Clinical Trials Logo

Glomerulonephritis, IGA clinical trials

View clinical trials related to Glomerulonephritis, IGA.

Filter by:

NCT ID: NCT02523768 Terminated - Glomerulonephritis Clinical Trials

Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment

PIRAT
Start date: January 8, 2011
Phase: Phase 4
Study type: Interventional

IgA nephropathy (IgAN) is a histologically defined glomerulonephritis (renal biopsy) by the presence of deposits immunoglobulin A (IgA) in the renal mesangium (at least 1+) by immunofluorescence. The clinic allows excluding secondary forms (10-15%). Recurrence of this condition on the renal graft is time-dependent and confirmed in 25 to 50% of 10 years post-transplant. The primary immunosuppressive induction regimens currently used in kidney transplantation are the anti-lymphocyte globulin (GAL) whose main target is human T lymphocytes (ATG, polyclonal) and monoclonal anti-CD25 antibodies (α chain of the interleukin receptor 2 in the surface of T lymphocytes). Due to their potent and prolonged immunosuppressive properties, the ATG may prevent or delay the recurrence on renal transplant. The aim of this study was to evaluate the influence of induction therapy (ATG versus Basiliximab) in the cumulative incidence at 5 years of (IgAN) recurrence after a first kidney transplant. This is a prospective, multicenter, randomized, open trial with a follow-up period of 5 years old. Patients in the ATG arm will receive 5 antilymphocyte globulin infusions Fresenius® (rabbit immunoglobulin antilymphocyte human T-Fresenius® said ATG) from Day 0 to Day + 4 post-transplant (day 0 one dose of 4mg / kg, day 1 one dose of 4mg/kg, day2 one dose of 4mgkg, day 3 one dose of 3 m/kg and day 4 and one final dose of 3 mg/kg) and the patients in the anti-CD25 arm will receive 2 doses of 20 mg of basiliximab (Simulect®) pn day 0 and day 4 after the graft. The maintenance immunosuppressive therapy is left to the discretion of the center. The primary endpoint will be the clinical and histological recurrence of IgAN defined by the presence of mesangial deposits of IgA (at least 1) by immunofluorescence on a biopsy of the graft triggered by the onset of proteinuria 1g/j and/or microalbuminuria greater than 300 mg / day.

NCT ID: NCT02493101 Completed - Lupus Nephritis Clinical Trials

The Correlation of Periostin and Renal Pathology in Chronic Kidney Disease Patients

Start date: April 2013
Phase: N/A
Study type: Observational

The purpose of this study is to determine the location of periostin and urine periostin level in patients with lupus nephritis and IgA nephropathy.

NCT ID: NCT02471599 Suspended - IgA Nephropathy Clinical Trials

Effect of Tonsillectomy on Longterm Renal Outcome of IgA Nephropathy

Start date: March 2011
Phase: N/A
Study type: Interventional

The effect of tonsillectomy therapy on IgA nephropathy is still controversial.Few prospective,randomized investigations have examined how tonsillectomy affects the shortterm and longterm renal outcome of IgA nephropathy.This is A prospective,randomized ,controlled study to explore the longterm effect of tonsillectomy for patients with IgA nephropathy.

NCT ID: NCT02433236 Withdrawn - IGA Nephropathy Clinical Trials

Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy

Start date: September 2015
Phase: Phase 2
Study type: Interventional

Phase 2, multi-center, open label extension study to evaluate 2 dose regimens of fostamatinib in approximately 25 subjects. The study will consist of 11 visits over 15 months.

NCT ID: NCT02384317 Completed - Clinical trials for Immunoglobulin A Nephropathy

Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade

Start date: March 27, 2015
Phase: Phase 2
Study type: Interventional

The primary safety objective of this study is to evaluate the safety and tolerability of CCX168 in subjects with IgAN on background supportive therapy with a maximally tolerated dose of RAAS blockade. The primary efficacy objective is to evaluate the efficacy of CCX168 based on an improvement in proteinuria.

NCT ID: NCT02382523 Withdrawn - Proteinuria Clinical Trials

Acthar on Proteinuria in IgA Nephropathy Patients

Start date: February 2015
Phase: Phase 4
Study type: Interventional

IgA nephropathy occurs when IgA—a protein that helps the body fight infections—settles in the kidneys. IgA deposits may cause the kidneys to leak blood and sometimes protein in the urine. Proteinuria (abnormal amounts of protein in urine) can be a sign of kidney damage. Current treatments for IgA nephropathy is limited to Angiotensin Converting Enzyme (ACE) inhibitor medications with fish oil. ACE Inhibitors, also called ACEI medications, slows the angiotensin converting enzyme so that blood vessels can be relaxed. This study involves the study drugs, Acthar and Lisinopril (an ACEI medication routinely given for high blood pressure). In previous clinical studies, some subjects with IgA nephropathy have experienced reductions in proteinuria with consistent use of Acthar. Acthar is approved by the Food and Drug Administration (FDA) and used to treat patients with proteinuria. The purpose is to study the safety and effectiveness of the study drug Acthar given at different doses.

NCT ID: NCT02351752 Completed - Clinical trials for Primary IgA Nephropathy

Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study

Start date: January 2015
Phase: Phase 4
Study type: Interventional

IgA nephropathy is the most common type of primary glomerulonephritis and might caused by deposition of immune complex containing IgA in mesangium and causing local immune activation. Hydroxychloroquine reduces the activation of dendritic cells and the inflammatory process and showed the potential effect of treatment of patients with IgA nephropathy. The investigators study will recruite IgA nephropathy patients with proteinuria range from 0.75 to 3.5g/d even after three-month treatment by sufficient ACEi/ARB. The patients were treated with Hydroxychloroquine 300-400mg/d according to eGFR. The proteinuria will recorded every two months and total four months. Then, the drug will be stopped for two months for observation of change of proteinuria.

NCT ID: NCT02282930 Completed - Proteinuria Clinical Trials

Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

Start date: March 2015
Phase: Phase 3
Study type: Interventional

This study is designed to answer whether patients with progressive IgA nephropathy, who receive Acthar (ACTH) gel injection at a dose of 80 units subcutaneously twice weekly for 6 months is effective in inducing improvement in proteinuria and renal function.

NCT ID: NCT02232776 Completed - Clinical trials for Glomerulonephritis, IGA

Efficacy and Safety of Losartan in Children With Ig A Nephropathy

Start date: October 2014
Phase: Phase 3
Study type: Interventional

The investigators hypothesize that using Losartan would help decrease proteinuria in controlling proteinuria in children with immunoglobulin A nephropathy.

NCT ID: NCT02231125 Recruiting - IgA Nephropathy Clinical Trials

Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy

Start date: September 2014
Phase: Phase 4
Study type: Interventional

-IgA nephropathy is the most common primary glomerular disease in China, Huangkui Capsule is a single medicament of traditional Chinese medicine consists of Abelmoschus manihot and has been widely used to treat kidney disease. The purpose of this study is to evaluate the safety and efficacy of Abelmoschus manihot for treating IgA nephropathy in large scale samples with long time take.